| 金聪慧,李 桃,倪静怡,张葆春,高湘湘.miR-592在乳腺癌组织中的表达及其与临床病理的相关性分析[J].现代生物医学进展英文版,2024,(15):2897-2901. |
| miR-592在乳腺癌组织中的表达及其与临床病理的相关性分析 |
| Expression of MiR-592 in Breast Cancer and Its Correlation with Clinicopathology |
| Received:February 04, 2024 Revised:February 25, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.15.017 |
| 中文关键词: miR-592 乳腺癌 淋巴结转移 临床分期 生存期 相关性 |
| 英文关键词: miR-592 Breast cancer Lymph node metastasis Clinical staging Survival period Relativity |
| 基金项目:江苏省卫健委指导性项目（Z2022036）；江苏省南通市科技计划指导性项目(JCZ21109)；江苏省南通市卫建委面上课题B（MB2021043） |
|
| Hits: 71 |
| Download times: 43 |
| 中文摘要: |
| 摘要 目的：探讨微小RNA（microRNA，miR）-592在乳腺癌组织中的表达及其与临床病理的相关性。方法：选取我院2018年1月到2019年12月收治的70例乳腺癌患者，分别采取患者的乳腺癌组织及癌旁组织进行免疫组化检测，检测miR-592表达水平。分析不同临床病理特征乳腺癌患者miR-592表达水平，采用Spearman相关性分析miR-592与乳腺癌临床病理的相关性。并对所有患者进行4年随访，记录乳腺癌患者的总生存时间，分析miR-592与乳腺癌生存期的关系。结果：乳腺癌组织miR-592相对表达量及阳性率明显低于癌旁组织（P＜0.05），免疫组化结果显示，乳腺癌组织显色比例明显低于癌旁正常组织；不同年龄、组织学类型、肿瘤大小、组织分化程度miR-592相对表达量对比无明显差异（P＞0.05），不同临床分期、淋巴结转移情况miR-592相对表达量对比差异显著（P＜0.05）；Spearman相关分析结果表明，miR-592与乳腺癌临床分期、淋巴结转移呈负相关（P＜0.05）；所有患者进行4年随访，miR-592高水平患者中位总生存时间为40.37（18.47~60.00）个月明显高于低水平患者中位总生存时间30.57（13.57~60.00）个月。结论：miR-592在乳腺癌组织中呈现低表达状态，与乳腺癌的临床分期、淋巴结转移情况相关，且miR-592低表达可能意味着乳腺癌患者预后不良。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the expression of microRNA (miR) -592 in breast cancer and its correlation with clinicopathology. Methods: 70 patients with breast cancer admitted to our hospital from January 2018 to December 2019 were selected, and their breast cancer tissues and adjacent tissues were taken for immunohistochemical detection to detect the expression level of miR-592. The expression level of miR-592 in breast cancer patients with different clinicopathological characteristics was analyzed, and the correlation between miR-592 and breast cancer clinicopathology was analyzed by Spearman correlation. All patients were followed up for 4 years to record the total survival time of breast cancer patients and analyze the relationship between miR-592 and the survival time of breast cancer patients. Results: The relative expression and positive rate of miR-592 in breast cancer tissues were significantly lower than those in adjacent tissues (P<0.05); There was no significant difference in the relative expression level of miR-592 among different ages, histological types, tumor sizes, and tissue differentiation levels (P>0.05), while there was a significant difference in the relative expression level of miR-592 among different clinical stages and lymph node metastases (P<0.05); Spearman correlation analysis showed that miR-592 was negative correlated with clinical stage and lymph node metastasis of breast cancer (P<0.05); After a 4-year follow-up, the median overall survival time of patients with high miR-592 was 40.37 (18.47 to 60.00) months, which was significantly higher than the median overall survival time of 30.57 (13.57 to 60.00) months. Conclusion: The low expression of miR-592 in breast cancer is related to the clinical stage and lymph node metastasis of breast cancer, and the low expression of miR-592 may mean poor prognosis of breast cancer patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
